Equity Snap: GSK (GSK LN): Q2 in line ex Arexvy, all eyes on growth program

研报英文原文证据摘录

Equity Snap: GSK (GSK LN): Q2 in line ex Arexvy, all eyes on growth program

ut the proprietary models used to produce this report, please contact

the authoring analyst.

HSBC may use Artificial Intelligence (AI) tools approved for adoption within HSBC in the development of its research reports,

utilizing these technologies to analyse large volumes of data, enhance efficiency and improve the overall user experience. This

includes but is not limited to paraphrasing, developing suitable captions and supporting data visualisation. It is important to note

that while AI tools assist in various aspects of report creation, all investment recommendations and opinions presented herein are

formulated and approved exclusively by our research analysts. The final content of the report reflects the professional judgement

and expertise of our research analysts, ensuring compliance with regulatory standards and maintaining the integrity of our

research process.

Additional disclosures

1 This report is dated as at 28 July 2026.

2 All market data included in this report are dated as at close 27 July 2026, unless a different date and/or a specific time of

day is indicated in the report.

3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its

Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of

Research operate and have a management reporting line independent of HSBC's Investment Banking business.

Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses

to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.